Equities

Neutra Corp

NTRR:PKL

Neutra Corp

Actions
  • Price (USD)0.0002
  • Today's Change0.000 / -20.00%
  • Shares traded1.09m
  • 1 Year change-66.67%
  • Beta3.1021
Data delayed at least 15 minutes, as of Jul 29 2024 14:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Neutra Corp. is an early-stage research and development company. The Company is engaged in marketing and participating in the nutraceutical space by bringing products derived from all natural and organic origins. The Company plans to research and bring new technology to the Nutraceutical space. The Company is primarily focused on participating in the medical cannabis market, which is a nutraceutical sub-market. It intends to entrust the manufacturing to a nutraceutical contractor to private label all of its products and to sell them under its brand. It primarily sells hemp-derived products, including products containing delta-8-THC and other cannabinoids. Its subsidiaries include Diamond Anvil Designs, LLC, Deity Corporation and Vivis Corporation.

  • Revenue in USD (TTM)17.40k
  • Net income in USD-474.98k
  • Incorporated2015
  • Employees--
  • Location
    Neutra Corp2500 CITYWEST BLVD., STE 150-161HOUSTON 77042United StatesUSA
  • Phone+1 (702) 793-4121
  • Websitehttps://neutrainc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gelstat Corp1.68m-1.22m157.50k2.00--0.0215--0.0937-0.0033-0.00330.00460.0140.30214.17--840,285.00-21.96---26.29--28.99---72.69--0.3216-134.790.0267---66.81---60.17------
Bioquest Corp0.00-507.41k260.72k-----------0.0485-0.04850.00-0.04670.00-------3,483.76-----------------3.88--------64.67------
Scisparc Ltd0.00-6.96m334.81k3.00--13.74-----1.22-1.510.000.03440.00----0.00-92.51-69.39-152.41-111.07-------527.17----0.9371--113.73---97.61------
Life Stem Genetics Inc0.00-568.02k393.34k1.00--0.21-----0.013-0.0130.000.00760.00----0.00-198.83---330.32--------------0.0241--------------
Bespoke Extracts Inc956.86k-1.36m508.43k10.00------0.5314-0.1331-0.13310.0941-0.1942.2920.1021.3695,686.00-325.13------45.50---141.75--0.0482-53.38----22,933.72--63.98------
ITonis Inc0.00-1.17m685.53k-----------0.0012-0.00120.00-0.00040.00-------187.63---1,169.36-------------0.8999---------506.86------
Evofem Biosciences Inc16.01m47.49m713.69k37.000.0012--0.0150.0446-5.92-5.920.0826-1.360.9351.722.73432,756.80295.02-211.64----63.65--315.54-1,031.550.0757-2.91----8.20--164.08---10.59--
Neutra Corp17.40k-474.98k729.47k--------41.92-0.0002-0.00020.00001-0.00030.27860.4126-----758.75-682.94----46.15---2,723.22-2,758.850.0009-14.06-----26.09--22.28------
Scorpius Holdings Inc9.74m-32.20m1.04m82.00--0.0132--0.1065-244.34-280.0573.26158.750.1372--26.56118,815.70-47.81-39.37-58.20-43.1868.56---348.43-1,068.210.2641-198.180.3179--1,789.583.841.96--27.32--
Agentix Corp0.00-1.01m1.05m-----------0.0253-0.02530.00-0.0710.00-------907.08-----------------96.41----------------
Data as of Jul 29 2024. Currency figures normalised to Neutra Corp's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.